Hypericum extract: Potential in the treatment of depression

CNS Drugs

Volumn 9, Issue 6, 1998, Pages 431-440

  Wheatley, David ^a,b  

^a CHELSEA AND WESTMINSTER HOSPITAL   (United Kingdom)

^b Charter Chelsea Clinic   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

AMITRIPTYLINE; ANTIDEPRESSANT AGENT; HYPERICUM EXTRACT; HYPERICUM PERFORATUM EXTRACT; IMIPRAMINE; MAPROTILINE; PLANT EXTRACT; PSYCHOTONIN M; SEROTONIN UPTAKE INHIBITOR; UNCLASSIFIED DRUG;

CHEMICAL ANALYSIS; CLINICAL TRIAL; DEPRESSION; DRUG EFFECT; DRUG EFFICACY; DRUG INDICATION; DRUG MECHANISM; HUMAN; HYPERICUM PERFORATUM; PRIORITY JOURNAL; REVIEW;

EID: 0031746458     PISSN: 11727047     EISSN: None     Source Type: Journal    
DOI: 10.2165/00023210-199809060-00002     Document Type: Review

References (56)

1. Lohse MJ, Muller-Oerlinghausen B. In: Schwabe U, Paffrath D., editors. Arznieverordnungsreport '94. Stuttgart: Gustav Fischer, 1994: 354-70
2. Monthly marketing data. Institute for Medical Statistics. Frankfurt: IMS, 1997 Dec
3. Coffey T. The history and folklore of North American wildflowers. Boston: Houghton Mifflin, 1993: 64-6
4. Grigson G. The Englishman's flora. London: Hart-Davis, MacGibbon, 1958: 83-9
5. Porcher FP. Resources of the southern fields and forests: medical, economical and agricultural: prepared and published by order of the surgeon-general. Richmond (VA) 1863. Reprint. New York: Arno Press, 1970
6. Nahrstedt A, Butterweek V. Biologically active and other constituents of the herb of Hypericum perforatum. Pharmacopsychiatry 1997; 30 Suppl. II: 129-34
7. Cott JM. In vitro receptor binding and enzyme inhibition by Hypericum perforatum extract. Pharmacopsychiatry 1997; 30 Suppl. II: 108-12
8. Müller WE, Rolli M, Schäfer C, et al. Effects of hypericum extract (LI 160) in biochemical models of antidepressant activity. Pharmacopsychiatry 1997; 30 Suppl. II: 102-7
9. Teufel-Mayer R, Gleitz J. Effects of long-term administration of hypericum extracts on the affinity and density of the central serotonergic 5-HT1A and 5-HT2A receptors. Pharmacopsychiatry 1997; 30 Suppl. II: 113-6
10. Özturk Y, Aydin S, Öturk N, et al. Effects of certain hypericum species on the central nervous system of mice [abstract]. Phytomedicine Int J Phytother Phytopharmacol 1996/7; 3 Suppl. 1: 102
11. Özturk Y. Testing of antidepressant effects of hypericum species on animal models. Pharmacopsychiatry 1997; 30 Suppl. 2: 125-8
12. Butterweck V, Wall A, Liefländer-Wulf, et al. Effects of the total extract and fractions of Hypericum perforatum in animal assays for antidepressant activity. Pharmacopsychiatry 1997; 30 Suppl. II: 117-24
13. Winterhoff H, Butterweck V, Nahrstedt A, et al. Pharmacologische Untersuchungen zur antidepressiven wirkung von Hypericum perforatum L. In: Loew D, Rietbrock N, editors. Phytopharmaca im forschund Klinischer anwendung. Steinkopf: Darmstadt, 1995: 39-56
14. Brockmöller J, Reum T, Bauer S, et al. Hypericin and pseudohypericin: pharmacokinetics and effects on photosensitivity in humans. Pharmacopsychiatry 1997; 30 Suppl. 2: 94-101
15. Linde K, Ramirez G, Mulrow CD, et al. St John's Wort for depression: an overview and meta-analysis of randomised clinical trials. BMJ 1996; 313: 253-8
16. Hänsgen KD, Vesper J, Ploch M. Multi-center double-blind study examining the antidepressant effectiveness of hypericum extract LI 160. J Geriatr Psychiatry Neurol 1994; 7 Suppl. 1: 15-8
17. Halama P, Wirksamkeit des Johanniskrautextractes L1 160 bei depressiver Verstimmung. Nervenheilkunde 1991; 10: 250-3
18. Harrer G, Schmidt U, Khun U. 'Alernative' depressions-hehandlungmit einem hypericum-extrakt. Therapiewoche Neurologie-Psychiatrie 1991; 5: 710-6
19. Hoffman J, Kuhl ED. Therapie von depressiver zustanden mit hypericin. Z Allgemeinmed 1979; 55: 776-82
20. Hübner WD, Lande S, Podzuweit H. Hypericum treatment of mild depression with somatic symptoms. J Geriatr Psychiatry Neurol 1994; 7 Suppl. 1: 12-5
21. Konig CD. Hypericum perforatum L (gemeines Johanniskraut) als Therapeutikum bei depressiven Verstimmungszustanden: eine Alternative zu synthetischen Arzneimittelin [thesis]. Basel: University of Basel, 1993
22. Lehrl S, Woelk H. Ergebnisse von Messungen der kognitiven Leistungsfähigkeit bei Patienten unter der Therapie mit Johanniskraut. Nervenheilkunde 1993; 12: 281-4
23. Osterheider M, Sehmidtke A, Beckmann H. Behandlung depressiver Syndrome mit Hypericum (Johanniskraut): eine placebokontrollierte Doppelblindstudie. Fortschr der Neurologie-Psychiatrie 1992; 60 Suppl. 2: 210-1
24. Quandt J, Schmidt U, Schenk N. Ambulante Behandlung leichter und mittelschwerer depressiver Verstimmungen. Der Allgemeinarzt 1993; 2: 97-102
25. Reh C, Laux P, Schenk N. Hypericum-Extrakt bei Depressionen: eine wirksame Alternative. Therapiewoche 1992; 42: 1576-81
26. Schlich D, Braukmann F, Beckmann H. Behandlung depressiver Zustände mit Hypericin. Zur Therapie depressiver Verstimmungen. Psycho 1987; 13: 440-7
27. Schmidt U, Schenk N, Schwartz I, et al. Zur Therapie depressiver Verstimmungen. Psycho 1989; 15: 665-71
28. Schmidt U, Sommer H. Johanniskraut-Extrakt zur ambulanten Therapie der Depression. Fortschr Med 1993; 111: 339-42
29. Sommer H, Harrer G. Placebo-controlled double-blind study examining the effectiveness of a hypericum preparation in 105 mildly depressed patients. J Geriatr Psychiatry Neurol 1994; 7 Suppl.: 9-11
30. Ditzler K, Gessner B, Schatton WFH, et al. Clinical trial on Neuropas versus placebo in patients with mild to moderate depressive symptoms: a placebo-controlled, randomised double-blind study. Complementary Ther Med 1994; 2: 5-13
31. Bergmann R, Nubner J, Demling J. Behandlung leichter bis mittelschwerer depressionen. Therapiewoche Neurologie-Psychiatrie 1993; 7: 235-40
32. Harrer G, Hubner WD, Podzuweit H. Effectiveness and tolerance of the hypericum extract LI 160 compared to maprotiline: a multi-center double blind study. J Geriatr Psychiatry Neurol 1994; 7 Suppl.: 24-8
33. Kugler J, Weidenhammer W, Schmidt A, et al. Therapie depressiver Zustände. Z Allgemeinmed 1990; 66: 21-9
34. Vorbach EU, Hubner WD, Arnoldt KH. Effectiveness and tolerance of the hypericum extract LI 160 in comparison with imipramine: randomized double-blind study in 135 outpatients. J Geriatr Psychiatry Neurol 1994; 7 Suppl. 1: 19-23
35. Warnecke G. Beeinflussung klimacterische Depressionen. Z Allgemeinmed 1986; 62: 1111-3
36. Vorbach EU, Arnold KH, Hubner WD. Efficacy and tolerability of St Johns Wort extract hypericum extract LI 160 in patients with severe depressive incidents according to ICD-10. Pharmacopsychiatry 1997; 30 Suppl.: 81-5
37. Kniebel R, Burchard JM. Therapie depressiver Verstimmungen in der praxis. Z Allgemeinmed 1986; 64: 689-96
38. Steger W. Depressiver verstimmungen. Z Allgemeinmed 1985; 61: 914-8
39. World Health Organization. International classification of diseases. 9th rev. Geneva: World Health Organization, 1988
40. World Health Organization. International classification of diseases. 10th rev. Geneva: World Health Organization, 1992
41. American Psychiatric Association. Diagnostic and statistical manual of mental disorders. 3rd rev. ed. Washington, DC: American Psychiatric Association, 1987
42. American Psychiatric Association. Diagnostic and statistical manual of mental disorders. 4th ed. Washington, DC: American Psychiatric Association, 1994
43. Wheatley D. LI 160, an extract of St. John's Wort, versus amitriptyline in mildy to moderately depressed outpatients a controlled 6-week clinical trial. Pharmacopsychiatry 1997; 30 Suppl. II: 77-80
44. Lane R, Baldwin D, Preskorn S. The SSRIs: advantages, disadvantages and differences. J Psychopharmacol 1995; 9 (2): 163-78
45. Woelk H, Burkhard G, Grunwald J. Benefits and risks of the Hypericum extract LI 160: drug monitoring with 3250 patients. J Geriatr Psychiatry Neurol 1994; 7 Suppl. I: 34-8
46. Leuschner J. Preclinical toxicological profile of hypericum extract LI 160 [abstract]. Phytomedicine Int J Phytother Phytopharmacol 1996/7; 3 Suppl. 1: 104
47. Beaumont G, Baldwin D, Lader M. A criticism of the practice of prescribing subtherapeutic doses of antidepressants for the treatment of depression. Hum Psychopharmacol 1996; 11: 283-91
48. Dunbar GC, Cohn LF, Feighner JP. A comparison of paroxetine, imipramine and placebo in depressed outpatients. Br J Psychiatry 1991; 159: 394-8
49. Mendels J, Johnson R, Mattes J, et al. Efficacy and safety of b.i.d. doses of venlafaxine in a dose-response study: Psychopharmacol Bull 1993; 29: 169-74
50. Rosenberg C, Damso N, Fuglum E, et al. Citalopram and imipramine in the treatment of depressive patients in general practice: a Nordic multicentre clinical study. Int Clin Psychopharmacol 1994; 9 Suppl. 1: 41-8
51. Fish D. What is an effective dose? [letter] BMJ 1997; 314: 826
52. Moore MV. More on what is an effective dose [letter]. BMJ 1997; 314: 826
53. Gill G. Systematic review of all pertinent trials is required to establish guidelines [letter]. BMJ 1997; 314: 826-7
54. Tan RS. Low dose tricyclic antidepressants are effective in treating major depression [letter]. BMJ 1997; 314: 827
55. Burrows GD, Norman T. Antidepressants: clinical aspects. Stress Med 1997; 13: 167-72
56. Wheatley D, Smith D, editors. Psychopharmacology of cognitive and psychiatric disorders in the elderly. London: Chapman & Hall, 1997